Back to Market返回行情

CRL Charles River Laboratories International, Inc.

USHealthcare
$233.41-0.08%ClosedMarket Cap: $11.24B

As of 2026-07-10 16:00

Why CRL matters now

Charles River Laboratories International, Inc. (CRL) is a US stock in Healthcare. The latest InvestLog snapshot shows $233.41 with -0.08% on the session and $11.24B in market capitalization; recent performance reads 1-month +21.37% and YTD -7.26%.

The latest financial table shown here is Q1 2026, with revenue of $995.8M, net income of $-14.8M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 4.4%.

The latest indexable market news headline is "Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is Buy with a median target of $219.00; recent insider activity includes Parisotto Shannon M filing G-Gift. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

3.08

P/S

2.21

EV/EBITDA

40.53

DCF Value

$105.51

FCF Yield

4.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

31.9%

Operating Margin

11.8%

Net Margin

-4.6%

ROE

-5.7%

ROA

-2.4%

ROIC

7.1%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$995.8M$-14.8M$-0.30
Q4 2025$994.2M$-276.6M$-5.62
FY 2025$4.02B$-144.3M$-2.91
Q3 2025$1.00B$54.4M$1.10

Analyst Ratings

Consensus

Buy

Target (Consensus)

$214.14

Target (Median)

$219.00

Target Range

$192.00 - $220.00

Strong Buy: 4Buy: 10Hold: 3Sell: 0Strong Sell: 1
Morgan StanleyOverweight
2026-06-17
CLSAOutperform
2026-05-29
BarclaysOverweight
2026-05-08
Evercore ISI GroupOutperform
2026-05-08
JP MorganNeutral
2026-04-13

Trading Activity

Insider Trades

Parisotto Shannon Mofficer: CEVP, Disc & Safety Assessment
Sell2026-06-08
Parisotto Shannon Mofficer: CEVP, Disc & Safety Assessment
Sell2026-06-08
Girshick Birgitofficer: Chief Executive Officer
Sell2026-06-08
Girshick Birgitofficer: Chief Executive Officer
Sell2026-06-08
FOSTER JAMES Cdirector
Sell2026-06-08

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

1.45

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.